NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. (“Enzymotec” or the “Company”) (Nasdaq:ENZY) common stock pursuant and/or traceable to the Company’s Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
For more information, click here: http://zlk.9nl.com/enzymotec-enzy.
The complaint alleges that Enzymotec’s Registration Statement and Prospectus contained materially false and misleading statements and omitted material information, and that throughout the Class Period the Company misrepresented and/or failed to disclose material information.
If you suffered a loss in Enzymotec you have until November 4, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/enzymotec-enzy.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.